Treatment of borderline personality disorder and co-occurring anxiety disorders.
Treatment of borderline personality disorder and co-occurring anxiety disorders.
复制标题
DOI：
10.12703/p5-15
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Valenstein HR
中科院分区：
文献类型：
--
作者：
Harned MS;Valenstein HR
焦虑症在边缘型人格障碍患者中非常普遍，共病率高达90%。研究发现，随着时间的推移，焦虑症降低了边缘型人格障碍缓解的可能性，并增加了这一人群自杀和自残的风险。对边缘型人格障碍的循证治疗还没有充分关注焦虑症，它们对这些障碍的影响要么有限，要么未知。相反，基于证据的焦虑症治疗通常排除自杀、自残和严重合并症患者，从而限制了其对边缘型人格障碍患者的推广。为了解决这些局限性，最近的研究开始集中于开发和评估对同时发生边缘性人格障碍和焦虑症的个体的治疗方法，特别是创伤后应激障碍（PTSD），并取得了有希望的初步结果。然而，这一领域还需要进一步的研究，特别是评估高危和复杂边缘型人格障碍患者的焦虑障碍治疗的研究。
Anxiety disorders are highly prevalent among individuals with borderline personality disorder, with comorbidity rates of up to 90%. Anxiety disorders have been found to reduce the likelihood of achieving remission from borderline personality disorder over time and to increase the risk of suicide and self-injury in this population. Evidence-based treatments for borderline personality disorder have not sufficiently focused on targeting anxiety disorders, and their effects on these disorders are either limited or unknown. Conversely, evidence-based treatments for anxiety disorders typically exclude suicidal, self-injuring, and seriously comorbid patients, thereby limiting their generalizability to individuals with borderline personality disorder. To address these limitations, recent research has begun to emerge focused on developing and evaluating treatments for individuals with co-occurring borderline personality disorder and anxiety disorders, specifically posttraumatic stress disorder (PTSD), with promising initial results. However, there is a need for additional research in this area, particularly studies evaluating the treatment of anxiety disorders among high-risk and complex borderline personality disorder patients.